Novartis’ Phase II post-operative corneal induced chronic pain (CICP) candidate SAF312 saw its Phase Transition Success Rate (PTSR) leap by nine points to 70% alongside a five-point bump in its Likelihood of Approval (LoA) to 37%, as of 7 June.

The change occurred after a series of updates were made to the Phase II study’s entry, between 6 May and 4 June. These included the addition of 14 trial locations and moving ahead the estimated primary completion date from 14 November 2022 to 24 October 2022.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. In the 150-patient Phase II trial patients receive twice-daily eye drops of a placebo or one of two doses of SAF312. The study is using a primary endpoint of change in mean pain severity. SAF312 is a non-narcotic analgesic and TRPV cation channel antagonist designed to treat postoperative ocular pain.

GlobalData’s analysis uses a combination of machine learning and its proprietary algorithm to identify the LoA. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Novartis has a market cap of $229.42bn.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.